These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9315418)

  • 1. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopy.
    Mauck CK; Baker JM; Barr SP; Johanson WM; Archer DF
    Contraception; 1997 Aug; 56(2):97-102. PubMed ID: 9315418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9. Postcoital testing and colposcopy.
    Mauck CK; Baker JM; Barr SP; Abercrombie TJ; Archer DF
    Contraception; 1997 Aug; 56(2):89-96. PubMed ID: 9315417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of Femcap used with and without spermicide. Postcoital testing.
    Mauck CK; Baker JM; Barr SP; Johanson W; Archer DF
    Contraception; 1997 Aug; 56(2):111-5. PubMed ID: 9315420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lea's Shield: a phase I postcoital study of a new contraceptive barrier device.
    Archer DF; Mauck CK; Viniegra-Sibal A; Anderson FD
    Contraception; 1995 Sep; 52(3):167-73. PubMed ID: 7587188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9.
    Mauck CK; Allen S; Baker JM; Barr SP; Abercrombie T; Archer DF
    Contraception; 1997 Aug; 56(2):103-10. PubMed ID: 9315419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of human sperm kinematics in cervical mucus due to nonoxynol-9.
    Dunmire EN; Katz DF
    Contraception; 1997 Apr; 55(4):209-17. PubMed ID: 9179452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I randomized postcoital testing and safety study of the Caya diaphragm used with 3% Nonoxynol-9 gel, ContraGel or no gel.
    Mauck CK; Brache V; Kimble T; Thurman A; Cochon L; Littlefield S; Linton K; Doncel GF; Schwartz JL
    Contraception; 2017 Aug; 96(2):124-130. PubMed ID: 28606382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compatibility between the spermicide nonoxynol 9 and mid-cycle human cervical mucus.
    Chantler E; Hemsworth M; Roach VP; Bruce JM
    Contraception; 1992 Sep; 46(3):289-95. PubMed ID: 1333387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful postcoital testing of Ovaprene: An investigational non-hormonal monthly vaginal contraceptive.
    Mauck C; Thurman A; Jensen JT; Schreiber CA; Baker J; Hou MY; Chavoustie S; Dart C; Wu H; Zack N; Hatheway J; Friend D
    Contraception; 2024 Apr; 132():110373. PubMed ID: 38232942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel.
    Amaral E; Faúndes A; Zaneveld L; Waller D; Garg S
    Contraception; 1999 Dec; 60(6):361-6. PubMed ID: 10715372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new vaginal antimicrobial contraceptive formulation: phase I clinical pilot studies.
    Ladipo OA; De Castro MP; Filho LC; Coutinho E; Waller DP; Cone F; Zaneveld LJ
    Contraception; 2000 Aug; 62(2):91-7. PubMed ID: 11102593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response effects of gramicidin-D, EDTA, and nonoxynol-9 on sperm motion parameters and acrosome status.
    Centola GM
    Contraception; 1998 Jul; 58(1):35-8. PubMed ID: 9743894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
    Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement and modulation of nonoxynol-9 diffusion and bioactivity against spermatozoa in human cervical mucus.
    Dunmire EN; Katz DF
    Contraception; 1997 Feb; 55(2):115-22. PubMed ID: 9071521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I comparative postcoital testing study of three concentrations of C31G.
    Mauck CK; Creinin MD; Barnhart KT; Ballagh SA; Archer DF; Callahan MM; Schmitz SW; Bax R
    Contraception; 2004 Sep; 70(3):227-31. PubMed ID: 15325892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SILCS diaphragm: postcoital testing of a new single-size contraceptive device.
    Schwartz JL; Ballagh SA; Creinin MD; Rountree RW; Kilbourne-Brook M; Mauck CK; Callahan MM
    Contraception; 2008 Sep; 78(3):237-44. PubMed ID: 18692615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product.
    Amaral E; Perdigão A; Souza MH; Mauck C; Waller D; Zaneveld L; Faúndes A
    Contraception; 2004 Dec; 70(6):492-7. PubMed ID: 15541412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The postcoital test as a method of evaluating a contraceptive jelly.
    Cohen MR; Kaye BM
    J Am Med Assoc; 1953 Jul; 152(11):1042-3. PubMed ID: 12255243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa.
    Niruthisard S; Roddy RE; Chutivongse S
    Sex Transm Dis; 1991; 18(3):176-9. PubMed ID: 1658953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZB-06, a vaginal film containing an engineered human contraceptive antibody (HC4-N), demonstrates safety and efficacy in a phase 1 postcoital test and safety study.
    Thurman AR; Moench TR; Hoke M; Politch JA; Cabral H; Mausser E; Nador E; Morton J; Hamorsky K; Swope K; Bratcher B; Anderson DJ; Whaley KJ
    Am J Obstet Gynecol; 2023 Jun; 228(6):716.e1-716.e12. PubMed ID: 36870409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.